semaglutide heart disease GLP-1 agonists like Ozempic may reduce cardiovascular events by 20% FDA Clears Semaglutide For Cardiac
Description
Patients who began GLP-1 medications in late 2024 and 2025 are now reaching stable goal weights and seeking solutions for excess skin that diet and exercise cannot resolve
Branded FDA-approved alternatives (Ozempic, Wegovy, Mounjaro, Zepbound) are also available at manufacturer pricing, which typically runs $800 to $1,400 per month
Too much or too little medication can be detrimental to your results
Bailey, C
Understanding where it fits helps researchers make informed decisions about which compound best serves their specific research questions
